Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ensysce Biosciences Inc (ENSC)

Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,575
  • Shares Outstanding, K 1,306
  • Annual Sales, $ 2,230 K
  • Annual Income, $ -10,610 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.60
  • Price/Sales 4.65
  • Price/Cash Flow N/A
  • Price/Book 1.12

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.34 +51.68%
on 12/13/24
9.82 -17.56%
on 11/21/24
-1.74 (-17.65%)
since 11/20/24
3-Month
2.12 +282.44%
on 10/15/24
14.67 -44.79%
on 11/07/24
+3.27 (+67.60%)
since 09/20/24
52-Week
2.12 +282.44%
on 10/15/24
30.90 -73.79%
on 01/24/24
-8.55 (-51.35%)
since 12/20/23

Most Recent Stories

More News
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

~ Supply Chain Now Fully Secure for PF614-MPAR ~

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~

ENSC : 8.10 (+1.89%)
Stocks Set to Open Mixed as Investors Await FOMC Minutes, U.S. Payrolls Data

September S&P 500 futures (ESU23) are down -0.08%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.01% this morning at the start of a holiday-shortened week, with market participants looking...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
AAPL : 254.49 (+1.88%)
NVDA : 134.70 (+3.08%)
MCHP : 55.51 (-0.86%)
ON : 65.50 (+1.08%)
CCL : 26.80 (+6.43%)
NKE : 76.94 (-0.21%)
G.M.DX : 26.990 (-0.18%)
TSLA : 421.06 (-3.46%)
NIO : 4.54 (+3.18%)
LI : 23.56 (+0.90%)
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study

Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences,...

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Secures $8 Million Convertible Note Financing

~ Additional Funding from Investor Cohort Validates Company's Mission ~

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)

Business Summary

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp.,...

See More

Key Turning Points

3rd Resistance Point 9.72
2nd Resistance Point 9.15
1st Resistance Point 8.63
Last Price 8.10
1st Support Level 7.53
2nd Support Level 6.96
3rd Support Level 6.44

See More

52-Week High 30.90
Fibonacci 61.8% 19.91
Fibonacci 50% 16.51
Fibonacci 38.2% 13.11
Last Price 8.10
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar